Figure 1
Pathophysiological mechanisms contributing to atherosclerotic cardiovascular disease. FFA: free fatty acid; IL-1: interleukin-1; IL-6: interleukin-6; PAI-1: plasminogen activator inhibitor-1; TNF-α: tumor necrosis factor alpha; MASLD: metabolic dysfunction-associated steatotic liver disease; NASH: nonalcoholic steatohepatitis
Figure 2
Social determinants of health implicated in increasing the risk of obesity and associated atherosclerotic cardiovascular disease.
Table 1
Strategies to reduce risk of obesity in patients with or at risk of atherosclerotic cardiovascular disease. SDoH: social determinants of health
| STRATEGY | TACTICS |
|---|---|
| Patient education | Assess patients’ comprehension of their treatment plans, verify their understanding, and personalize clinical strategies to align with each patient’s needs |
| Community engagement to address SDoH/Community outreach initiatives | Educate expectant mothers on the importance of balanced nutrition, healthy weight management, and regular physical activity Develop community partnerships to encourage healthy lifestyles |
| Dedicated cardiometabolic and cardiovascular prevention clinics | Conduct routine obesity screening during medical visits for children and adolescents Consistently monitor patients with obesity at risk for cardiovascular disease |